ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
admin 8th September 2017 Uncategorised 0In May, AstraZeneca stunned the market with news that its PD-L1 med Imfinzi had succeeded in significantly delaying time to cancer progression in the lung-cancer maintenance setting. And now, the company is unveiling just how long that delay was.
More: ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
Source: fierce